Combining BCL-2 inhibitors with HyperCVAD for treating T-lymphoblastic leukemia/lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of BCL-2 inhibitors in combination with the HyperCVAD regimen for patients newly diagnosed with T-lymphoblastic leukemia or lymphoma. Patients in the experimental group will receive this combination treatment, while a control group will be formed using historical data from similar patients. The study will assess the complete remission rate after induction chemotherapy as the primary endpoint, alongside secondary endpoints such as duration of remission, progression-free survival, overall survival, and adverse events. Propensity score matching will be utilized to ensure comparability between groups based on key clinical factors.

Why it matters

Who can join: the full rules

Inclusion Criteria Age 18-60 years, regardless of gender; Expected survival time greater than 12 weeks; ECOG score 0-2; Pathologically or flow cytometrically confirmed as T-cell lymphoblastic lymphoma, with less than 25% tumor cell proportion in bone marrow smears;

Liver and kidney function, as well as cardiopulmonary function, meet the following requirements:

Creatinine clearance (calculated using the Cockcroft-Gault formula) ≥60 mL/min; Left ventricular ejection fraction greater than 50%, with no clinically significant ECG changes; Baseline oxygen saturation greater than 92% Total bilirubin ≤1.5×ULN; ALT and AST ≤3×ULN Able to understand the trial and has signed the informed consent form Exclusion Criteria A history of acute T-cell leukemia, T-cell lymphoma, or T-cell lymphoblastic lymphoma within the past 5 years, except for adequately treated carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or thyroid cancer after radical surgery Active bacterial, viral, or fungal infections that require treatment and are not controlled; those who are HBsAg or HBcAb positive, with peripheral blood HBV DNA ≥ the lower limit of detection; individuals who are positive for hepatitis C virus antibodies and have positive peripheral blood HCV RNA; individuals who test positive for syphilis (TRUST test); individuals who are positive for human immunodeficiency virus (HIV) antibodies Dysfunction of important organs (cardiovascular, pulmonary) or a history of active gastrointestinal bleeding within the past 3 months; individuals with uncontrolled hypertension, hypertensive crisis, or a history of hypertensive encephalopathy, and a history or evidence of significant cardiovascular risk, including any of the following: congestive heart failure, unstable angina, clinically significant arrhythmias (e.g., ventricular fibrillation, ventricular tachycardia); a history of arterial thrombosis within the past 3 months (e.g., stroke, transient ischemic attack); a history of symptomatic deep vein thrombosis, pulmonary embolism within the past 6 months, or a history of coronary angioplasty, defibrillation, or any clinical complications or diseases that may pose a risk to the participant\'s safety or interfere with the evaluation, procedures, or completion of the study Any uncontrolled active disease that may interfere with participation in the trial; Active, uncontrolled central nervous system diseases or a history of central nervous system disease requiring treatment (e.g., epilepsy) Pregnant or breastfeeding women; and individuals planning to become pregnant within 1 year after infusion, during treatment, or after treatment ends Presence of uncontrolled active infections (except for simple urinary tract infections or upper respiratory infections Known allergies to any components of cyclophosphamide, doxorubicin, vincristine, cytarabine, methotrexate, etc.

Any situation that the investigator believes would compromise participant safety or interfere with the study objectives, or any individual deemed inappropriate for participation by the investigator Individuals with diseases affecting their ability to sign the written informed consent form or comply with study procedures; those unwilling or unable to adhere to study requirements

Where it's running

• Shanghai General Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Xianmin Song，MD
• Email: shongxm@139.com
• Phone: +8613501672508

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for adult patients with specific types of lymphoma and leukemia

  This study is testing a new treatment plan using a combination of medications before a stem cell transplant to see if it helps adults with certain types of lymphoma and leukemia stay in remission.

  Recruiting Phase 1 Fifth Affiliated Hospital, Sun Yat-Sen University · Zhuhai, Guangdong · NCT06060782

• Sonrotoclax plus azacitidine in high-risk MDS with increased blasts-2

  This study tests whether adding sonrotoclax to azacitidine can help people with newly diagnosed high-risk MDS with increased blasts-2 see better disease control and tolerable safety.

  Recruiting Phase 1/2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 5 other locations · NCT07885397

• Acupuncture to Improve Sleep and Reduce Pain After Lung Cancer Surgery (VATS)

  This trial tests whether acupuncture given around surgery can improve sleep and lessen chronic pain for adults undergoing video-assisted thoracoscopic lung cancer removal.

  Recruiting at 2 sites Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 1 other locations · NCT07662733

• STN-targeted non-invasive brain stimulation for Parkinson’s symptoms

  A non-invasive procedure called tTIS is tested in people with Parkinson’s to see if it helps motor and non-motor symptoms.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07625540

• Nimotuzumab plus Immunotherapy and Chemotherapy before surgery for locally advanced head and neck cancer

  This phase 2 trial tests whether adding nimotuzumab to immunotherapy and chemotherapy before surgery helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07601737

• Risk predictor for new urinary incontinence after prolapse surgery

  This study tests a model to predict which women might develop new stress urinary incontinence after pelvic organ prolapse repair.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07601282

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.